arrow
S

Stephen B. Heitner

Department of Clinical Research
H指数:33
被引数:6,652

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Aficamten在非梗阻性肥厚型心肌病患者的安全性与有效性:FOREST-HCM研究96周分析

2025-09-280
OAAI
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

梗阻性肥厚型心肌病患者使用Aficamten治疗后房颤发生率低:REDWOOD-HCM、SEQUOIA-HCM和FOREST-HCM试验的分析

2025-08-310
OAAI
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial

血清镁与射血分数降低的心力衰竭的结局:GALACTIC-HF试验

2025-08-011
OAAI
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten 治疗:有症状性梗阻性肥厚型心肌病

2025-06-190
PRE
Reply to: Correction to external evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard

回复:针对商业人工智能增强型数字听诊平台的体外评估在瓣膜性心脏病检测中的修正(以超声心动图作为参考标准)

2025-05-150
PRE
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial

阿菲坎坦在梗阻性肥厚型心肌病伴轻度症状患者中的疗效:SEQUOIA-HCM试验结果

2025-05-012
OAAI
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

阿菲坎坦与丙吡胺联用治疗症状性梗阻性肥厚型心肌病

2025-04-020
OAAI
Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial

Aficamten在FOREST-HCM试验中,对符合室间隔减容治疗指南适应证患者的疗效与安全性

2024-11-120
PRE
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Aficamten在症状性非梗阻性肥厚型心肌病中的疗效和安全性: 来自REDWOOD-HCM试验的结果,队列4

2024-11-017
OAAI
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
2024-11-011
PRE